Grup de Recerca en Medicina Aplicada Hospital Joan XXIII, Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, IISPV, Tarragona, Spain.
Clin Endocrinol (Oxf). 2012 Nov;77(5):691-8. doi: 10.1111/j.1365-2265.2011.04327.x.
The controversial results on the physiopathological role of visfatin led us to examine both circulating visfatin levels and gene expression in visceral (VAT) and subcutaneous fat (SAT) in a homogeneous group of morbidly obese women.
DESIGN, PATIENTS AND MEASUREMENTS: We analysed circulating levels of several adipo/cytokines in 133 Spanish women: 40 lean (C) [body mass index (BMI) < 25 kg/m(2) ] and 93 morbidly obese (MO) (BMI > 40 kg/m(2) ). In the MO group, we found 31 diabetic and 62 nondiabetic subjects. We obtained follow-up blood samples at 6 and 12 months after bariatric surgery from 30 MO patients. We determined the circulating levels of visfatin, adiponectin, interleukin-6 (IL6), C-reactive protein (CRP), resistin and tumour necrosis factor-α (TNFα) by ELISA, and visfatin, adiponectin, IL6, resistin and TNFα gene expression in SAT and VAT by real-time RT-PCR.
Circulating visfatin levels were higher in MO women compared with lean controls (C = 1·43 ± 0·14 μg/l, MO = 3·60 ± 0·29 μg/l, P < 0·001). After bariatric surgery-induced weight loss, visfatin levels were reduced significantly over 12 months. Visfatin expression in SAT and VAT was similar, but significantly higher in MO compared to C and independent of the presence of diabetes mellitus. Circulating visfatin levels were positively related to IL6 and CRP levels. Visfatin gene expression in VAT and SAT was strongly related to IL6 and TNFα expression.
In a homogeneous cohort of morbidly obese women, our findings show that visfatin has a strong relationship with pro-inflammatory factors in severe obesity.
内脏脂肪组织(VAT)和皮下脂肪组织(SAT)中内脏脂肪素(visfatin)的基因表达及其循环水平在肥胖患者中的变化仍存在争议。本研究旨在观察肥胖患者 VAT 和 SAT 中 visfatin 的基因表达,并分析其与循环脂肪因子的关系。
设计、患者及检测指标:分析了 133 名西班牙女性的几种脂肪细胞因子的循环水平,其中 40 名体质量正常者(BMI<25 kg/m2)为对照组(C),93 名病态肥胖者(BMI>40 kg/m2)为病例组(MO)。MO 组中,31 名患者为糖尿病患者,62 名患者为非糖尿病患者。对 30 名 MO 患者进行随访,在减重手术后 6 和 12 个月时采集血样。采用 ELISA 法检测循环 visfatin、脂联素、白细胞介素-6(IL-6)、C 反应蛋白(CRP)、抵抗素和肿瘤坏死因子-α(TNF-α)的水平,采用实时 RT-PCR 法检测 SAT 和 VAT 中 visfatin、脂联素、IL-6、抵抗素和 TNF-α的基因表达。
MO 患者的循环 visfatin 水平显著高于对照组(C 组:1.43±0.14 μg/L;MO 组:3.60±0.29 μg/L,P<0.001)。减重手术后,MO 患者的循环 visfatin 水平随体重的降低而显著下降。SAT 和 VAT 中的 visfatin 表达水平相似,但 MO 组的表达水平显著高于 C 组,且与糖尿病无关。循环 visfatin 水平与 IL-6 和 CRP 水平呈正相关。VAT 和 SAT 中的 visfatin 基因表达与 IL-6 和 TNF-α的表达密切相关。
在同质肥胖患者队列中,本研究结果表明,visfatin 与严重肥胖患者的促炎因子有很强的相关性。